Patent ID: 11931410
Assignee: SHENZHEN RHEGEN BIOTECHNOLOGY CO., LTD.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 14:
15. The SARS-CoV-2 mRNA vaccine according to claim 13, wherein the ionizable lipid includes, but is not limited to, one or more of (dilinoleyl)methyl 4-(N,N-dimethylamino)butanoate, SM-102, and ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate);
the positively charged lipid includes, but is not limited to, one or more of DOTMA and DOTAP;
the neutral auxiliary lipid includes, but is not limited to, one or more of DSPC, DOPE, and DSPE; and
the PEGylated lipid includes, but is not limited to, one or more of methoxypoly(ethylene glycol) ditetradecylacetamide and DMG-PEG.